Unternehmensübersicht
Hoth Therapeutics, Inc. operates as a clinical-stage biopharmaceutical enterprise dedicated to advancing therapies designed to address significant unmet medical needs within the healthcare sector. The company specifically focuses on the development of HT-001, a topical formulation currently undergoing Phase II clinical trials for the management of rash and skin disorders arising from initial and repeat treatment courses. This entity functions within the biotechnology industry, a high-risk, high-reward segment of the healthcare market characterized by substantial research and development expenditures prior to commercialization. The firm currently maintains a market capitalization of $10.76M, employs 2 individuals, and reports N/A for its trailing twelve-month revenue, which collectively indicates an early-stage operational scale typical of pre-commercial biotechnology ventures.
Finanzielle Gesundheit
The company reports a net income of $-12,469,302 over the trailing twelve months, while its revenue, EBITDA, and free cash flow are all recorded at N/A or negative figures, specifically with free cash flow at $-5,543,313. Although specific revenue figures are not disclosed in the available data, the substantial negative net income relative to the reported free cash flow suggests a cost structure where operational expenses and R&D investments significantly outpace current income generation. The gross margin stands at 0.0%, the operating margin at 0.0%, and the profit margin at 0.0%, all of which reflect the typical financial reality of a clinical-stage company where costs are incurred before any sales revenue materializes. Regarding liquidity, the company holds $6.25M in cash against a minimal debt burden of $5,678, resulting in a debt-to-equity ratio of 0.09 that characterizes a highly conservative balance sheet with negligible leverage. The current ratio is recorded at 4.72, indicating a robust position in short-term liquidity where current assets substantially exceed current liabilities, providing ample room to fund ongoing clinical operations. Furthermore, the return on equity is -191.4% and the return on assets is -100.9%, metrics that reveal that management has yet to generate positive returns on the capital invested, a common characteristic for entities still in the development phase of their asset portfolio.
Bewertungsanalyse
Valuation metrics for Hoth Therapeutics, Inc. present a mixed picture typical of unprofitable biotechnology firms, with a P/E Ratio (TTM) listed as N/A and a Forward P/E of -0.79. The absence of a trailing P/E ratio implies that the company has not yet generated sufficient earnings to support a standard multiple, while the negative forward P/E suggests that analysts or market models project continued losses in the immediate future rather than an imminent earnings turnaround. The price-to-book ratio is stated at 1.42, indicating that the market values the company's equity at 42% above its book value, a premium that reflects the potential value of its intellectual property and pipeline assets despite current financial losses. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are both N/A, suggesting that traditional sales-based or earnings-based valuation multiples are not applicable for a firm with no sales revenue and negative earnings. The stock has exhibited significant volatility over the past year, trading between a 52-week low of $0.50 and a 52-week high of $2.12. Based on the provided high and low, the current trading environment allows for analysis of price compression, though the exact current price is not explicitly defined in the source data to calculate a precise percentage deviation from the high. The beta is 0.60, which indicates that the stock's price volatility is historically 40% lower than the broader market, suggesting a lower systematic risk profile compared to large-cap equities despite the inherent risks of the biotechnology sector.
Growth & Income
Hoth Therapeutics, Inc. reports N/A for both revenue growth (YoY) and earnings growth (YoY), reflecting the fact that the company has not yet reached a stage where year-over-year percentage comparisons are meaningful due to the absence of commercial revenue. Since the firm does not pay a dividend, with a dividend yield of N/A and a payout ratio of 0.0%, it follows the standard practice for clinical-stage biotechs of reinvesting all available capital and retained earnings directly into research, development, and clinical trial expansion rather than distributing cash to shareholders. The company's overall growth and income profile is currently defined by its reliance on external capital markets to sustain operations, as internal cash generation is insufficient to fund growth or provide income to investors. Consequently, the firm's strategy focuses entirely on advancing its pipeline to commercial viability, foregoing any current income generation to build long-term value potential in the treatment of skin disorders associated with medical therapy courses.